At BIOVECTRA we specialize in clinical-to-commercial scale production capabilities for biologics, synthetic small molecules, pDNA/mRNA manufacturing, highly potent APIs, and bioreagents. Reach out and let us know what challenges we can solve.
With over 50 years of experience, we are a forward-thinking, North American CDMO specializing in clinical-to-commercial scale production of high-quality regulated APIs and Intermediates.
Industry Master Degree from Frankfurt Chamber of Commerce, Frankfurt Germany.
More than 20 years of global pharmaceutical industry experience.
Held numerous leadership positions in commercial development, marketing and brand management, and lifecycle management and has extensive product launch and market access expertise in Europe and North America.
In 1997, joined Eisai GmbH in Frankfurt, Germany and in 2002, was appointed Director, CNS Business Unit; in 2006, was appointed Vice President, Head of Global Marketing for Eisai Inc. in Woodcliff Lake, NJ; in 2011, was appointed Vice President, Established Products Business Unit; in 2013, was appointed President & General Manager for Eisai Limited in Mississauga, ON.
Appointed President of BIOVECTRA Inc., December 10, 2015.
Board Director for BIOTECanada
Member of the Steering Council of Innovative Medicines Canada (IMC)
In 2017, appointed to the Government of Canada’s Health/Bio-sciences Strategic Economic Table
In November 2019, promoted to Chief Executive Officer at BIOVECTRA
In June 2020, named new Chair of PEI BioAlliance Board of Directors